DSpace university logo mark
Advanced Search
Japanese | English 

NAOSITE : Nagasaki University's Academic Output SITE > School of Medicine > Articles in academic journal >

Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir


File Description SizeFormat
BioRes10_156.pdf559.6 kBAdobe PDFEmbargo until 2019-08-04

Title: Changes in serum LDL, PCSK9 and microRNA‑122 in patients with chronic HCV infection receiving Daclatasvir/Asunaprevir
Authors: Ichikawa, Tatsuki / Miyaaki, Hisamitsu / Miuma, Satoshi / Taura, Naota / Motoyoshi, Yasuhide / Akahoshi, Hiroshi / Nakamura, Junpei / Takahashi, Youichi / Honda, Tetsurou / Yajima, Hiroyuki / Uehara, Ryouhei / Hino, Naoyuki / Narita, Syouhei / Tanaka, Hisaya / Sasaki, Seina / Nakao, Kazuhiko
Issue Date: 4-Feb-2019
Publisher: Spandidos Publications
Citation: Biomedical Reports, 10(3), pp.156-164; 2019
Abstract: The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9),microRNA (miR)122 and low‑density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b infection with Daclatasvir/Asunaprevir. A total of 39 patients with HCV genotype 1b infection with chronic hepatitis received a 24‑week treatment regimen of Daclatasvir/Asunaprevir. Laboratory data were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment.Serum miR122 and PCSK9 were measured at the start of treatment (week 0), end of treatment (week 24), 4 weeks after the end of treatment (week 28),12 weeks after the end of treatment (week 36) and 28 weeks after the end of treatment (week 52). LDL was increased at week 4 after the start of treatment to week 52. The increased LDL/HDL ratio at week 52 compared with week 4 was also associated with relative miR122 at week 52 At week 4,PCSK9‑active form (A) was lower than that at other time points, and PCSK9‑inactive form (I) exhibited the greatest increase. At week 52,PCSK9‑A was higher than that during treatment, but PCSK9‑I level at week 52 did not markedly differ from that any time point except for week 4. Relative miR122 at week 4 was associated with increased PCSK9‑A at weeks 36 and 52 from the start of DAA. In summary, treatment of HCV with Daclatasvir/Asunaprevir resulted in elevated LDL, and relative miR122 and PCSK9‑A levels in serum appeared to have some association with LDL increase.
Keywords: Direct acting anti‑virals / Hepatitis Cvirus / Low‑density lipoprotein / MicroRNA122 / Protein convertase subtilisin/kexin 9
URI: http://hdl.handle.net/10069/38954
ISSN: 20499434
DOI: 10.3892/br.2019.1189
Rights: © 2019, Spandidos Publications.
Type: Journal Article
Text Version: publisher
Appears in Collections:Articles in academic journal

Citable URI : http://hdl.handle.net/10069/38954

All items in NAOSITE are protected by copyright, with all rights reserved.

 

Valid XHTML 1.0! Copyright © 2006-2015 Nagasaki University Library - Feedback Powerd by DSpace